oCular Examination at Cell RESolution With Optical TransmissionTomography

Launched by CENTRE HOSPITALIER NATIONAL D'OPHTALMOLOGIE DES QUINZE-VINGTS · May 15, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new eye imaging technology called optical transmission tomography (OTT) that aims to improve how we diagnose and understand eye diseases, particularly glaucoma and other conditions affecting the front parts of the eye. Traditional imaging methods have limitations, but OTT provides clearer images with better detail, which can help doctors see and assess eye health more effectively.

The trial is looking for participants aged 18 to 80, including both patients with eye diseases like glaucoma or cataracts and healthy volunteers without any eye issues. To participate, individuals must be covered by the French Assurance Maladie and agree to take part by signing a consent form. During the study, participants can expect to undergo eye examinations using this new imaging technology, which could contribute to better future treatments for eye conditions. It's important to note that some people, such as those with certain medical devices or active eye infections, may not be eligible to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• For Patients:
• • 200 subjects aged 18 to 80 years;
• • Male or female;
• • with an ocular disease affecting the cornea, ocular surface, lens (cataract) or glaucoma, or requiring refractive surgery or post-refractive surgery follow-up;
• • Are covered by the French Assurance Maladie;
• • Have signed an express, free and informed consent form.
• For Healthy volunteers:
• • 100 subjects aged 18 to 80 years;
• • Male or female;
• • Healthy subjects with no known pathology directly or indirectly affecting ocular structures;
• • Covered by the French Assurance Maladie.
• • Having signed an express, free and informed consent form.
• Exclusion Criteria:
• For all participants:
• • Inability to hold a still position on a standard ophthalmic chin rest;
• • Conjunctivitis or other contagious contact disease in active phase;
• • Having an implanted pacemaker or other electronic medical device;
• • Having a predisposition to iridocorneal angle closure;
• • Vulnerable persons or persons under legal protection (pregnant or breast-feeding women; persons under guardianship,